HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

ss III or IV angina refractory to medical therapy who also had multivessel occlusive coronary artery disease not amenable to revascularization. Patients were treated in dose-escalating fashion at 200, 800 or 2,000 mg dose, injected directly into the heart muscle with a hypodermic needle after a mini-thoracotomy, a surgical incision in the chest wall.

Patients were followed for clinical events after one year by hospital records, follow-up visits or telephone contact. At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) had Class II angina, while the remaining had Class I or II angina. Compared to baseline, average angina class decreased from 3.6 0.5 to 1.3 1.0 after the first year. This benefit persisted to 24 months when the mean angina class was 1.5 1.2 (p< 0.05).

Major clinical events such as death, myocardial infarction (MI, or heart attack) and repeat revascularization were uncommon during the first year but more frequent after one year at a rate consistent with the severity of the underlying disease in a population with advanced atherosclerosis. The majority of events were the result of progression of disease in areas of the heart remote from the site of injection.

Previous Clinical Data

Physicians who participated in the Phase I study published previous reports stating that the results demonstrated the safety of VEGF-2 and citing significant improvement in the exercise tolerance time in all dose groups. The study reports reflected that 80% of the patients treated experienced an improvement (decrease) in angina class of two or more levels and 40% of the patients experienced complete elimination of angina symptoms. Similarly, significant reductions in the number of angina episodes per week and the number of nitroglycerin tablets taken were observed. Given the invasive nature of this trial, there was not a control group that received a placebo.

The Phase I trial was followe
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
(Date:7/2/2015)... ... July 02, 2015 , ... Maddock Douglas is ... and business models. To help manage the increasing demand for innovation as a ... as SVP of Strategic Engagements. , Benkendorf is a seasoned management executive with ...
(Date:7/1/2015)... Mich. (PRWEB) , ... July 01, 2015 , ... ... transition of Catholic sponsorship complete, St. Joseph’s Health, located in Syracuse, N.Y., is ... the closing today, we have gained an admirable and important partner committed to ...
(Date:7/1/2015)... New York, New York (PRWEB) , ... July ... ... drug injury lawsuit filed against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has ... the U.S. District Court, Southern District of West Virginia on June 26th, the ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... ... July 01, 2015 , ... A ... organically raised chickens and eggs. Eating organic foods and products can help limit ... more environmentally friendly than production chicken farming. Choosing home raised chickens and eggs ...
Breaking Medicine News(10 mins):Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2
(Date:7/1/2015)... , July 1, 2015  AVACEN, Inc. announced today the ... patent covering the medical technology platform supporting its unique Dry ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... methods patent no. 9,066,781 - Methods And Apparatus For Therapeutic ... AVACEN and specific methods of use, referred to by the ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek ... company focused on chronic inflammatory disease and neurologic disorders, ... principle study with anatabine citrate, the Company,s lead compound. ... dose of anatabine citrate can significantly inhibit the activation ... The Company is developing this compound in a Phase ...
(Date:7/1/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... president and chief executive officer, is scheduled to ... provide an update on Egalet,s marketed product ... approved product OXAYDO ™ (oxycodone HCI, USP) ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
Cached News: